Giao dịch BioNTech BNTX

Bán
 Mua

BioNTech biểu đồ trực tiếp

5m 15m 30m 1h 4h 1d 1w

Kiến thức cơ bản về công cụ

Weekly Search
Weekly
Daily
Ngày Đóng Thay đổi % Thay đổi Mở Cao Thấp

BioNTech news

Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Tin tức mới nhất

Cho xem nhiều hơn
Tommy Yap 2025 Jul 07, 16:00

Morning Note: RBA Holds Rates; Trump Tariffs Hit; Tesla Dips on Musk News

Morning Note Stocks Central Banks
Frances Wang 2025 Jul 06, 16:00

Stock market today: Dow, S&P 500, Nasdaq futures fall, Sensex, Nifty update

Stocks Indices
Frances Wang 2025 Jul 06, 16:00

Lumber Stocks to Watch: SSD stock, UFPI stock, HD stock

Stocks
Frances Wang 2025 Jul 06, 16:00

Oil Price Is Under $70: Where is Oil Price Expected to Go?

Commodities
Tommy Yap 2025 Jul 06, 16:00

Morning Note: Dollar Near Lows on Tariffs; US Eyes AI Chip Curbs; Ethereum’s Future

Morning Note Forex Cryptocurrencies
monetary Policy
Tommy Yap 2025 Jul 05, 21:00

Week Ahead: Monetary Policy Focus Turns to RBA and RBNZ

Forex Indices
Ghko B 2025 Jul 03, 16:00

Solana Price Gains 4%: What is the price target for Solana?

Cryptocurrencies
Frances Wang 2025 Jul 03, 16:00

Bitcoin Price Outlook: What will be the value of Bitcoin in 2025?

Cryptocurrencies

Thông tin

Chênh lệch

0.7300

Tỷ lệ Spread (%)

0.6559 %

Đòn bẩy

1:10

Lãi suất Qua đêm Mua

-0.0597 %

Lãi suất Qua đêm Bán

-0.0292 %

Forex

USD

Giờ giao dịch

Thị trường đã đóng cửa.

Thứ tư

13:31 - 19:59

Thứ hai

13:31-19:59

Thứ ba

13:31-19:59

Thứ năm

13:31-19:59

Thứ sáu

13:31-19:59

Phân tích và thống kê

Mở

---

Đóng trước đó

---

52 Tuần Cao/Thấp

--- – ---

Giá trị vốn hóa thị trường

26455472128

Cổ phiếu nổi bật

240395008

Ngày báo cáo thu nhập (tiếp theo)

0000-00-00

Tỷ suất cổ tức

2022-06-17

Ngày giao dịch không hưởng quyền

2022-06-02

Tỷ lệ cổ tức thường niên kỳ hạn

0

Tỷ suất cổ tức thường niên kỳ hạn

0

EPS

-3.75

Tìm hiểu thêm về công cụ này

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Các công cụ liên quan

Tài sản
Bán
Mua
% Thay đổi

Giao dịch ngay

Giao dịch ngay

Giao dịch ngay

Giao dịch ngay
Các công cụ liên quan

latest_education_articles

Cho xem nhiều hơn
Trustpilot